The members of the Cognos Therapeutics, Inc. (Cognos) Neuro-Oncology Board are renowned medical experts in their fields. They have multidisciplinary expertise in translational research and affinity with pharma/drug/device development. Their affiliations are global and they have broad network associations in their respective medical communities.
The Cognos Neuro-Oncology Board is an advisory organ for the executive board of Cognos. The Neuro-Oncology Board provides advice from a clinical point of view about the design, context and content of Cognos’ ongoing research and product development. In addition the Neuro-Oncology Board advises Cognos on project proposals as it relates to internal and external funding efforts by the company. The Neuro-Oncology Board informs Cognos about relevant new clinical insights and developments.
Thomas Chen, MD, PhD
Dr. Chen serves as Chairman of the Board for the Cognos Therapeutics’ Neuro-Oncology Board. He is a physician, a board certified neurosurgeon, and the Director of Surgical Neuro-oncology at USC. Dr. Chen’s ability to bridge innovative vision and real-world application is critical to the Cognos mission.
Mitchel Berger, MD
Dr. Mitchell Berger is a nationally recognized expert in the treatment of brain and spinal cord tumors and tumor-related epilepsy in adults and children. In addition he is a specialist in brain mapping techniques with over 30 years in neurosurgical practice.
Jeffrey N. Bruce, MD, FACS
Dr. Bruce is a leading authority on complex tumors of the brain and skull base. As Co-Director of the Brain Tumor Center, the Bartoli Brain Tumor Research Laboratory, and The Pituitary Tumor Center, Dr. Bruce leads is a leading authority in translational brain tumor research effort with interests in immunotherapy and drug delivery systems.
Marc Charles Chamberlain, MD
Dr. Chamberlain is a professor of neurology at the University of Washington’s Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance. Dr. Chamberlain has published more than 175 papers and is the developer of many of the methods used in evaluating and managing neoplastic meningitis.
Lisa M. DeAngelis, MD
Dr. Lisa DeAngelis is a neuro-oncologist with extensive experience in the care of patients with brain tumors and the neurologic complications of cancer. She has led national trials of investigational drugs for primary CNS lymphoma and has conducted numerous trials of brain tumor therapeutics.
Frederick F. Lang Jr., MD, FACS, FAANS
Dr. Lang is a leader in the field of neurosurgery. He is the recipient of numerous awards including America’s Top Doctors for Cancer, the Preuss Research Award, and the Michael S. Voynick Award in Neuro-Oncology. He has over 150 published peer-reviewed articles and book chapters.
Norman Scott Litofsky, MD
Dr. Norman Scott Litofsky is a professor and chief of the division of neurological surgery at the University of Missouri School of Medicine. He was the principle investigator for cell acquisition and maintenance core for the NCI-funded program project, Neural Stem Cells and Neuro-Oncology.
Russell R. Lonser, MD
Dr. Russell Lonser is a professor and Chair of the Department of Neurological Surgery at Ohio State University’s Wexner Medical Center. Dr. Lonser’s laboratory and translational research interests include development of direct nervous system drug delivery paradigms for targeted therapy, as well as investigation of tumor pathogenesis and biology in familial neoplasia syndromes.
Kevin O’Neill, MD
Dr. O’Neill is Consultant Neurosurgeon and Head of Neurosurgery at Charing Cross Hospital, Imperial College NHS Trust and an Honorary Senior Lecturer in the Division of Clinical Neuroscience at the Imperial College in London. He is also the Head of Neurosurgery at Charing Cross Hospital.
John Howard Sampson, MD, PhD
Dr. Sampson is an internationally recognized neurosurgeon and has received a number of national and international awards and grants in recognition of his expertise in neuro-oncology and especially in the area of immunotherapy for brain tumors. He currently is the Chief of the Division of Neurosurgery at Duke University.
Andrew Edward Sloan, MD, FAANS, FACS
Dr. Sloan currently serves as Director of the Brain Tumor and Neuro-Oncology Center for Case Western University Medical School. Dr. Sloan is an award-winning, respected and noted leader in the field of Neurosurgery with deep experience in the pathology and treatment of gliomas and other brain cancers.
Michael Vogelbaum, MD, PhD, FACS
Dr. Vogelbaum is an Associate Director of the Brain Tumor and Neuro-Oncology Center and Director of the Center for translational Therapeutics at Cleveland Clinic. He specializes in the diagnosis and treatment of tumors of the brain and spinal cord.
Manfred Westphal, MD
Dr. Westphal is the Director for the Department of Neurosurgery at the University Clinic Hamburg-Eppendorf. In addition he is a member of the German Academy of Neurosurgery and the European Association of Neurosurgical Societies. Dr. Westphal has published more than 230 Medline listed publications and 50 book chapters.